Literature DB >> 12717625

Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection.

Jeannette N Williams1, Graeme R Jones, Myron Christodoulides, John E Heckels.   

Abstract

The association between individual meningococcal antigens and the development of protective immunity to both serogroup C and B meningococci was studied before and during an outbreak of serogroup C infection among university students. Persons who became infected showed, in serum taken either before infection or on admission to the hospital, low levels of bactericidal activity against the outbreak strain; patients who survived infection developed bactericidal activity that correlated with production of antibodies to serogroup C capsular polysaccharide but not to either lipopolysaccharide or major outer-membrane proteins. Uninfected classmates also showed a strong correlation between bactericidal activity and the presence of anti-capsular antibodies. In contrast, bactericidal activity against serogroup B did not correlate with the presence of antibodies to capsular polysaccharide but did correlate with antibodies reacting with the porin proteins PorA and PorB. These studies support the introduction of conjugate MenC vaccines, validate strategies for prevention of serogroup B infection that are based on vaccines containing PorA, and suggest that PorB may also be an important component of such vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717625     DOI: 10.1086/374648

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

3.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

5.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 6.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Berhanu Melak; Degu Berhanu; Morten Harboe; Jan Kolberg; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

8.  Seroprevalence of bactericidal antibodies against serogroup B and C Meningococci in a University Hospital.

Authors:  C A C Gioia; A P S Lemos; M C O Gorla; R Mendoza-Sassi; B S Figueredo; T Ballester; A Von Groll; B Wedig; N V Ethur; L Bragança; P E A Silva; L G Milagres
Journal:  Braz J Med Biol Res       Date:  2017-04-20       Impact factor: 2.590

9.  Structure of the Neisseria Adhesin Complex Protein (ACP) and its role as a novel lysozyme inhibitor.

Authors:  María Victoria Humbert; Amaka Marian Awanye; Lu-Yun Lian; Jeremy P Derrick; Myron Christodoulides
Journal:  PLoS Pathog       Date:  2017-06-29       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.